Low-Density Lipoprotein (LDL) is Associated with Earlier Progression in Synchronous Metastatic Colorectal Cancer Treated Without Curative Intent

Overview

Journal J Gastrointest Cancer

Publisher Springer

Date 2025 Feb 5

PMID 39907838

Authors

Erman Akkus

Nejat Emre Oksuz

Gungor Utkan

Affiliations

Soon will be listed here.

Abstract

Background: Low-density lipoprotein cholesterol (LDL) is associated with the occurrence of colorectal cancer (CRC). This study aims to investigate its prognostic role and associated clinicopathological factors in the metastatic setting.

Methods: Patients with newly diagnosed synchronous metastatic CRC were included. Patients were grouped according to the serum LDL levels at the diagnosis (≤ 130 mg/dL: Normal-LDL, > 130 mg/dL: High-LDL). LDL-associated clinicopathological factors, progression-free survival (PFS), and overall survival (OS) were assessed.

Results: A total of 90 patients were included. 44.4% (n = 40) was in the normal-LDL and 56.6% (n = 50) in the high-LDL group. Colonic localization of the primary tumor was more frequent in the high-LDL group (90% vs. 67.5%, p = 0.009). The high-LDL group more frequently had local treatments [metastasectomy (26% vs. 2.5%, p = 0.002) and embolization-ablation (38% vs. 17.5%, p = 0.033)]. Despite higher curative intent with local treatments in the high-LDL group, PFS [10.03 months (95% Confidence Interval (CI):6.97-14.77) vs 9.63 mo. (95% CI: 7.93-14.00), p = 0.872] and OS [20.87 mo. (95% CI: 14.87-36.47) vs. 17.63 mo. (95% CI: 14.30-43.03), p = 0.925] did not differ from the normal-LDL. Among patients treated without any curative intent, high LDL was associated with significantly worse PFS [4.97 mo. (95% CI: 3.00-7.73) vs. 8.43 mo. (95% CI: 6.10-9.90), p = 0.048].

Conclusion: This study suggests that serum LDL is associated with colonic primary localization in synchronous metastatic CRC. Levels > 130 mg/dL at diagnosis may be associated with worse survival and may be further investigated as a biomarker. Larger, multicenter and prospective studies are needed.

References

Siegel R, Wagle N, Cercek A, Smith R, Jemal A . Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023; 73(3):233-254. DOI: 10.3322/caac.21772. View

Biller L, Schrag D . Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021; 325(7):669-685. DOI: 10.1001/jama.2021.0106. View

Yang Z, Tang H, Lu S, Sun X, Rao B . Relationship between serum lipid level and colorectal cancer: a systemic review and meta-analysis. BMJ Open. 2022; 12(6):e052373. PMC: 9226934. DOI: 10.1136/bmjopen-2021-052373. View

Mayengbam S, Singh A, Yaduvanshi H, Bhati F, Deshmukh B, Athavale D . Cholesterol reprograms glucose and lipid metabolism to promote proliferation in colon cancer cells. Cancer Metab. 2023; 11(1):15. PMC: 10500936. DOI: 10.1186/s40170-023-00315-1. View

Tartter P, Slater G, Papatestas A, AUFSES Jr A . Cholesterol, weight, height, Quetelet's index, and colon cancer recurrence. J Surg Oncol. 1984; 27(4):232-5. DOI: 10.1002/jso.2930270407. View

Loffler L, Mashkoor M, Gogenur I, Gogenur M . Associations between pre-operative cholesterol levels with long-term survival after colorectal cancer surgery: a nationwide propensity score-matched cohort study. Int J Colorectal Dis. 2024; 39(1):159. PMC: 11467112. DOI: 10.1007/s00384-024-04735-3. View

Liao F, He W, Jiang C, Yin C, Guo G, Chen X . A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C. Onco Targets Ther. 2015; 8:3135-42. PMC: 4629979. DOI: 10.2147/OTT.S90479. View

Jellinger P, Handelsman Y, Rosenblit P, Bloomgarden Z, Fonseca V, Garber A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017; 23(Suppl 2):1-87. DOI: 10.4158/EP171764.APPGL. View

Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J . Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(1):10-32. DOI: 10.1016/j.annonc.2022.10.003. View

10.

Luo X, Tu Z, Chen H, Ding J . Blood lipids and risk of colon or rectal cancer: a Mendelian randomization study. J Cancer Res Clin Oncol. 2021; 147(12):3591-3599. DOI: 10.1007/s00432-021-03790-5. View

11.

Paschke S, Jafarov S, Staib L, Kreuser E, Maulbecker-Armstrong C, Roitman M . Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer. Int J Mol Sci. 2018; 19(9). PMC: 6165083. DOI: 10.3390/ijms19092577. View

12.

Deng L, Gui Z, Zhao L, Wang J, Shen L . Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012; 57(6):1576-85. DOI: 10.1007/s10620-012-2055-1. View

13.

Almuradova E, Yalcin S, Arikan R, Ayhan M, Demir H, Cevik G . Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus. 2023; 15(5):e39119. PMC: 10195643. DOI: 10.7759/cureus.39119. View

14.

Zwickl H, Hackner K, Kofeler H, Krzizek E, Muqaku B, Pils D . Reduced LDL-Cholesterol and Reduced Total Cholesterol as Potential Indicators of Early Cancer in Male Treatment-Naïve Cancer Patients With Pre-cachexia and Cachexia. Front Oncol. 2020; 10:1262. PMC: 7417624. DOI: 10.3389/fonc.2020.01262. View

15.

Wang Z, Wang Y, Li Z, Xue W, Hu S, Kong X . Lipid metabolism as a target for cancer drug resistance: progress and prospects. Front Pharmacol. 2023; 14:1274335. PMC: 10571713. DOI: 10.3389/fphar.2023.1274335. View

16.

Zeineddine F, Zeineddine M, Yousef A, Gu Y, Chowdhury S, Dasari A . Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023; 7(1):16. PMC: 9925745. DOI: 10.1038/s41698-023-00353-4. View

17.

Brantley K, Riis A, Erichsen R, Thorlacius-Ussing O, Moller H, Lash T . The association of serum lipid levels with colorectal cancer recurrence. Cancer Epidemiol. 2020; 66:101725. DOI: 10.1016/j.canep.2020.101725. View

18.

Hong T, Shen D, Chen X, Wu X, Hua D . Preoperative serum lipid profile and outcome in nonmetastatic colorectal cancer. Chronic Dis Transl Med. 2017; 2(4):241-249. PMC: 5643756. DOI: 10.1016/j.cdtm.2016.11.015. View

19.

Maeda-Minami A, Takagi M, Mano Y, Ishikawa H, Matsuyama Y, Mutoh M . Association between Statins and Incidence of Cancer in Patients with Dyslipidemia Using Large-Scale Health Insurance Claims Data. Cancer Prev Res (Phila). 2022; 16(1):37-45. DOI: 10.1158/1940-6207.CAPR-22-0087. View

20.

Gu J, Zhu N, Li H, Zhao T, Zhang C, Liao D . Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. Cell Oncol (Dordr). 2022; 45(5):709-728. DOI: 10.1007/s13402-022-00694-5. View